Overview

Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Status:
Active, not recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment. To explore the efficacy of vemurafenib as a single agent across diverse type of tumors guided by the presence of identified activating molecular alterations in the vemurafenib target gene, per cohort.

Phase:

Phase 2

Details

Lead Sponsor:

UNICANCER

Collaborators:

Fondation ARC
Hoffmann-La Roche
National Cancer Institute, France

Treatments:

Vemurafenib